Drug Profile
Recombinant epidermal growth factor - Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals
Alternative Names: Heberprot-P; Heberprot-P 75; hrecEGF; rhEGF; rhuEGFLatest Information Update: 26 Jun 2020
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology; Praxis Pharmaceuticals
- Class Antiulcers; Growth factors
- Mechanism of Action Epidermal growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Diabetic foot ulcer
Most Recent Events
- 01 Jun 2020 Praxis and the CIGB suspends a phase II trial in Diabetic foot ulcer in Cuba (RPCEC00000048)
- 11 Aug 2013 Registered for Diabetic foot ulcer in Angola (Intralesional)
- 31 Jan 2013 Heberprot-P is available for licensing in selected territories as of 31 Jan 2013. www.icgeb.org/